Key Highlights
● Third-quarter Revenue was $341.3 million, up 8.9% from $313.3 million.
● Net income rose to $26.3 million, or $0.32 per diluted share.
● Adjusted EBITDA increased 6.3% to $58.4 million.
● Cash and marketable securities were $195.6 million, with no debt.
Progyny, Inc. (NASDAQ:PGNY), a fertility and family-building benefits manager, raised the midpoint of its full-year 2026 outlook when it reported third-quarter results on Nov. 4. The updated ranges leave a defined set of expectations for the final quarter of the year, a period that comes just before most of the company's newly signed clients are expected to go live. For investors, the fourth-quarter guidance offers a near-term benchmark for how utilization, pharmacy revenue and profitability may be trending into 2027. Those ranges are management guidance, and they provide a framework against which the next report can be measured.
Latest Company Context
In the third quarter, Progyny reported revenue of $341.3 million, up 8.9% from $313.3 million. Fertility benefit services revenue rose 10.6% to $223.4 million, while pharmacy benefit services grew 5.8% to $117.9 million. Gross Margin improved to 24.5% from 23.2%, and Net Income rose to $26.3 million, or $0.32 per diluted share, from $13.9 million. Adjusted EBITDA increased 6.3% to $58.4 million. The company served 607 clients with an average of 7.18 million members, and ended the quarter with $195.6 million in cash and marketable securities and no Debt after repurchasing about 3 million shares for $82.7 million. Adjusted EPS was $0.52 compared with $0.45. Nearly 11 million shares have been repurchased in 2026 to date, and the company's $200 million revolving Credit Facility remains undrawn.
Key Business and index Drivers
The company's full-year 2026 guidance now calls for revenue of $1.365 billion to $1.385 billion, net income of $107.0 million to $110.6 million and adjusted EBITDA of $235 million to $240 million. For the fourth quarter specifically, management guided to revenue of $344.7 million to $364.7 million, net income of $28.5 million to $32.1 million, or $0.36 to $0.41 per diluted share, and adjusted EBITDA of $57.9 million to $62.9 million.
At the midpoint, that revenue range implies growth from the third quarter, which may reflect member utilization patterns and treatment timing. Utilization is a key variable: third-quarter assisted reproductive technology cycles rose to 16,723, and all-member utilization edged up to 0.56% from 0.54%. Pharmacy revenue has grown more slowly than fertility services, so the mix between the two could influence gross margin. Lower share count from Buybacks also supports per-share figures. Full-year adjusted EPS guidance stands at $2.09 to $2.13, with fourth-quarter adjusted EPS guided to $0.53 to $0.58.
What Investors Should Watch
The fourth-quarter and full-year 2026 report, which management has said will include initial 2027 guidance and is expected in February 2027, is the next major identifiable catalyst. Investors may compare actual results with the fourth-quarter ranges, particularly the net income and adjusted EBITDA midpoints. Commentary on the onboarding of new clients, most of which are expected to launch in the first quarter of 2027, could indicate whether implementation is proceeding on schedule; the company has said it expects more than 660 clients and about 8.3 million covered lives once those launches are complete. The remaining roughly $51 million under the buyback authorization, and whether the board expands it, may also be watched. Employer benefit budgets and healthcare cost trends are broader factors.
Fourth-Quarter Markers Before 2027 Guidance
Progyny's raised outlook gives investors specific fourth-quarter markers to measure against before 2027 guidance arrives. Results relative to those ranges, along with utilization and pharmacy trends, could shape expectations for a year in which the company expects a larger client base. These figures are management guidance rather than reported outcomes, and actual results may differ. The company's debt-free Balance Sheet and ongoing buybacks add another dimension to how per-share results may evolve. Investors may also consider how quickly new clients ramp up utilization after launch.






Please wait processing your request...